Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)

A. Santoro,W.-C. Su,A. Navarro,M. Simonelli,J.C.-H. Yang,A. Ardizzoni,F. Barlesi,J.H. Kang,S. Didominick,A. Abdelhady,B. Goswami,A. Crystal,E. Felip

Annals of Oncology（2018）

Cited 0|Views0
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined